[Control of temporary anticoagulation in extracorporeal circulation using activated coagulation time]
Related Experiment Video
Updated: Oct 14, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Abstract:
The customary use of standardized regimens for heparin anticoagulation and its neutralization by protamine in cardiopulmonary bypass may result in gross over- or underdosage of either substance with resulting clinical problems. Heparin and protamine doses, postoperative blood loss during the first 20 h and the need for bank blood in a group of 100 patients following a fixed heparin-protamine protocol were compared with another group of 106 cases with ACT-guided heparin and protamine dosage. In the ACT-group the mean heparin dose was 22.5% less (3.57 mg/kg and 4.60 mg/kg respectively) than in the standard group. Protamine doses fell by 58.5% from 5.11 mg/kg to 2.12 mg/kg in the ACT-group. The mean postoperative blood loss in the ACT-cases was 4.54 ml/kg/20h, 2.29 ml respectively 33.5% less than that of control group. The demand for bank blood in the ACT-group was 1.97 units opposed to 5.12 units in the standardized regimen group.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Venous Thrombosis III: Interprofessional Care

